IKNA (ikenaoncology.com) Book Value per Share

Graphic logo of Ikena Oncology, Inc. (IKNA)

The book value per share dynamics for Ikena Oncology, Inc. (IKNA) are based on partnerships with scientific centers researching cell survival pathways. Asset growth relies on the future launch of targeted lung tumor therapy, although the absence of market premiums and a resource-saving regime limit capital. The value of 28.54 captures the current state of the parameter, concluding the current trend in the company's asset changes.

IKNA (Ikena) Accounting Value per Share history from 07/04/2022 to 08/09/2025
Mass-produced product of Ikena Oncology Inc.

Ikena Oncology, Inc. (IKNA) is currently operating in a strict resource-saving mode, concentrating all efforts on testing a single priority drug. The BVPS valuation trend reflects the net equity per share, calculated as the difference between all assets and liabilities; the stable trend of this line confirms the preservation of the company's asset base during the R&D pipeline optimization period.

Main competitors

ONC - Net Assets per Single Share|HALO (Halozyme Corp) - Equity per Share|RVMD: Book Value per Share|ascentage.com (AAPG) - Book Value per Share|CGON (CG Oncology) - Book Value per Share|Accounting Value per Share UroGen Pharma Ltd (URGN)|Book Value per Share BCAX|Book Value per Share Personalis Genomics (PSNL)|Net Assets per Single Share Erasca, Inc. ERAS|DCTH: Equity per Share|Y-mAbs Therapeutics, Inc. - Book Value per Share|Aura Biosciences Inc (AURA) - Accounting Value per Share|CADL: Book Value per Share|Net Asset Value per Share Accuray, Inc. (ARAY)|Net Assets per Single Share SELLAS Life Sciences Group, Inc.|ACTU: Accounting Value of a Share|Accounting Value per Share CTOR (Citius Oncology)|HURA (tuhurabio.com) - Accounting Value of a Share|Book Value per Share TARA (Protara)|FATE - Accounting Value per Share|WHWK: Accounting Value per Share|TCRX - Book Value per Share|championsoncology.com (CSBR) - Net Assets per Single Share|XBiotech - Accounting Value of a Share|CVM (CEL-SCI Corp.) - Book Value per Share|Net Asset Value per Share OS Therapies, Inc. OSTX|Book Value per Share RADX|Net Assets per Share artivabio.com|Net Assets per Single Share Adlai Nortye ANL|Book Value per Share Veru Inc VERU|Tempest Tx - Book Value per Share|Net Asset Value per Share Xilio Therapeutics, Inc.|renovarobio.com (RENB) - Net Assets per Single Share|Equity per Share MURA|KAPA (Kairos Pharma Limited) - Book Value per Share|Book Value per Share OnKure|Accounting Value per Share GDTC (CytoMed Therapeutics)|CRIS (curis.com) - Accounting Value of a Share|Net Assets per Single Share Apollomics APLM|tharimmune.com (THAR) - Net Asset Value per Share|ADVB - Net Assets per Single Share|GNPX (Genprex Inc.) - Equity per Share|CLDI: Book Value per Share|Accounting Value per Share Sunshine Biopharma Inc.|Net Assets per Single Share Xenetic Biosciences Inc.|Net Asset Value per Share salariuspharma.com SLRX|Net Assets per Single Share Purple Biotech Ltd. (PPBT)|Net Assets per Single Share AONC (aoncology.com)|Net Assets per Single Share BeOne Medicines BGNE|Checkpoint Therapeutics Inc (CKPT) - Net Asset Value per Share|Elevation Oncology, Inc. - Book Value per Share|Book Value of One Share iCAD, Inc. (ICAD)|NTBL (Notable Labs) - Accounting Value per Share|Net Asset Value per Share Viracta Therapeutics, Inc. (VIRX)|Accounting Value per Share MOR|NAYA: Accounting Value of a Share|Book Value per Share AAPGV